Latest News
Astellas Pharma Inc.
- Japan's Astellas Pharma inks $400 M deal with AI Proteins to develop novel miniprotein-based therapeutics
- Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma
- Astellas and AI Proteins sign miniprotein therapeutics deal
- Astellas Pharma Inc. Advanced Charts | 4503
- Astellas links up with AI Proteins in $400M computational drug discovery deal
- AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million
- Will Fast Track Status Change Astellas Pharma Stock Narrative
- Radhika Ranganath Announces Retirement as Astellas Senior Global Medical Director
- Astellas Presents Enfortumab Vedotin-Pembrolizumab Data at ESMO 2026
- Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
- Sathya Narayana Begins New Role as Medical Scientific Liaison – Oncology at Astellas Pharma
- Astellas launches Phase 3 trial of KRAS G12D-targeted drug in advanced lung cancer
Headlines from the last 30 days, linking to the original publishers. See all market news →